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Eosinophilic esophagitis (EoE) is an emerging disease characterized by esophageal
eosinophilia (>15eos/hpf), lack of responsiveness to acid-suppressive medication and is
managed by allergen elimination and anti-allergy therapy. Although the pathophysiology of
EoE is currently unsubstantiated, evidence implicates food and aeroallergen hypersensitiv-
ity in genetically predisposed individuals as contributory factors. Genome-wide expression
analyses have isolated a remarkably conserved gene-expression profile irrespective of age
and gender, suggesting a genetic contribution. EoE has characteristics of mainly TH2 type
immune responses but also some TH1 cytokines, which appear to strongly contribute to
tissue fibrosis, with esophageal epithelial cells providing a hospitable environment for this
inflammatory process. Eosinophil-degranulation products appear to play a central role in
tissue remodeling in EoE.This remodeling and dysregulation predisposes to fibrosis. Mast-
cell-derived molecules such as histamine may have an effect on enteric nerves and may
also act in concert with transforming growth factor-β to interfere with esophageal mus-
culature. Additionally, the esophageal epithelium may facilitate the inflammatory process
under pathogenic contexts such as in EoE. This article aims to discuss the contributory
factors in the pathophysiology of EoE.
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INTRODUCTION
Eosinophilic esophagitis (EoE) is an emerging condition char-
acterized by severe isolated eosinophilic infiltration of the
esophageal mucosa (1). It is unresponsive to acid-suppressive
medication but responsive to the removal of dietary antigens
and steroid anti-inflammatory medications (2). The identifica-
tion of EoE as a disease occurred following investigations into
treatment resistant patients with gastro-esophageal reflux dis-
ease (GERD) (3). The similarity in presentation of EoE and
GERD necessitates the correlation of clinical and pathologi-
cal findings and the establishment of diagnostic criteria dif-
ferentiating the two diseases, to ensure accurate diagnosis and
management (4).
The most recently updated consensus recommendations from
The First International Gastrointestinal Research Symposium
(FINGERS) state that EoE is a chronic clinicohistopathological dis-
order characterized by a myriad of symptoms distinct and similar
to those of GERD (5). Clinically, EoE symptomatology varies with
age, but is characterized by symptoms suggestive of esophageal
dysfunction including dysphagia, abdominal pain, and episodes of
food impactions. Children typically present with failure to thrive,
vomiting, and heartburn (6).
Research has also identified specific endoscopic and histologic
features more characteristic of EoE than GERD. Endoscopic find-
ings such as rings, strictures, narrowed esophagus, linear furrows,
crepe-paper mucosa, and white plaques along with histologi-
cal findings such as maximal eosinophil counts greater than 15
eosinophils per high-powered-field (hpf), eosinophil microab-
scesses, eosinophil degranulation, spongiosis, and subepithelial
fibrosis are more common in EoE patients than those with
GERD (6, 7).
However, emerging evidence questions the reliability of using
eosinophil counts as diagnostic of EoE. Some cases of GERD
also meet these criteria of eosinophil numbers, indicating that
this feature alone would introduce error in distinguishing EoE
from GERD (6). While historically, unresponsiveness to acid-
suppression therapy with high esophageal eosinophil density was
pathognomonic of EoE, studies now show molecular and histo-
logical features that differentiate EoE from GERD (6). Increased
awareness of features that define EoE has allowed more accurate
diagnoses and enhanced management of patients.
Frequently, but not always, patients presenting with EoE have
a history of food (8) or aeroallergen (9) hypersensitivity, elevated
serum immunoglobulin (Ig)E, and responsiveness to diet restric-
tion (8,10) or anti-allergy therapy (11,12). However, some patients
with EoE have normal IgE levels. While the documented cytokine
expression profile in the esophageal tissue in patients with EoE
is that of a TH2 inflammatory response (13), TH1 cytokines have
also been shown to be up-regulated in some patients. The later
favors a type IV hypersensitivity (cell mediated) mechanism, and
may explain the non-IgE cases of EoE (14).
This article aims to discuss the current understanding of
the roles of eosinophils, mast cells, cytokines, chemokines, and
esophageal epithelial cells, in the pathophysiology of EoE.
EPIDEMIOLOGY
A number of studies have determined the prevalence of EoE in
selected populations: some have suggested an increasing incidence
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of disease. The estimated prevalence of EoE in a pediatric popula-
tion in Hamilton County, Ohio between 2000 and 2003, was ~4 in
10,000 with an incidence of 0.9–1.3 in 10,000 new cases per year
(15). A 16-year long study on an adult Swiss cohort observed simi-
lar prevalence (~2/10,000) and incidence (1.4/100,000) rates (16).
However, despite the increase in esophagogastroduodenal biop-
sies between 1982 and 1999, a retrospective study examining 666
patients found the incidence of EoE to be relatively stable during
this time period (16). As such enhanced disease recognition rather
than true increase in disease incidence may be contributing to the
emergence of EoE as a high prevalence clinicopathologic entity.
Case reports of EoE are mainly from industrialized coun-
tries such as Australia, North America, Europe, and East Asia,
with isolated reports from South America. Reports from African-
American populations have been scarce (16, 17). EoE predom-
inates in Caucasian (81%) (18) middle aged (30–40 years) men
(72%) (17), although cases have been reported from all ages and
ethnic backgrounds (19, 20). This observed higher disease rate in
Caucasians compared to other ethnicities raises questions about
race as a confounding factor in the pathophysiology of EoE. In a
recent study comparing the clinical presentations of adult patients
with EoE, Sperry et al. (17), suggested that African-American
patients were younger at diagnosis, were more likely to present
with failure to thrive and less likely to have esophageal rings than
Caucasian patients. Whether the lower prevalence of the African-
American population with EoE is attributable to misdiagnosis due
to currently unknown presentations or a true lower prevalence, is
uncertain. More research is required to fully establish the role of
ethnicity in the pathophysiology of EoE.
Research showing seasonal variations of EoE have postulated
that environmental factors may modify the presentation of EoE.
Some investigators have reported an increase in the incidence
of EoE during spring and summer seasons (21). However, these
findings are controversial. Hurrel et al. (22) found a high preva-
lence of esophageal eosinophilia in adult patients living within the
colder geographical climates of the US compared to those living
in warmer areas. Other similar studies have also not supported
seasonal variations (23).
GENETIC HERITABILITY
Accumulating evidence has shown a strong familial association in
EoE (15). Zink et al. (24) reported EoE to span over two gen-
erations in five out of seven families studied. In the same study,
a longer term follow-up found a family history of EoE in 5 out
of 30 patients with the condition. Concordantly, Noel et al. (15)
found 6.8% of 103 pediatric patients with EoE to have a family his-
tory of dysphagia. EoE also exhibits a high sibling risk ratio (λS),
defined as the ratio of disease manifestation given that one’s sib-
ling is affected, of ~80, compared to other atopic diseases such as
asthma (λS ~ 2) (25). To allow comparison, inflammatory bowel
disease, a condition known to run in families has a λS of 0.83 (26).
Interestingly, recent studies have demonstrated the coexistence of
EoE with another genetically inherited condition, celiac disease
(CD) (27, 28), further highlighting a possible genetic contribution
to EoE.
Several candidate genes for EoE have been identified.
CCL26/eotaxin-3 gene, based on genome-wide association studies
(GWAS), is the most highly expressed gene in EoE, being
up-regulated between 50- and 100-fold in EoE patients (29). How-
ever, this disease-associated allele has only been found in 14% of
cases (30), highlighting the contributions of other risk variants.
More recently, Rothenberg et al. (29) identified and replicated a
significant locus at 5q22.1 in European cases of EoE. The two genes
that map to this locus are TSLP andWDR36 (29). TSLP encodes a
cytokine similar to interleukin (IL)-7 produced in the thymus and
peripheral tissues, and acts to regulate TH2 responses (31). WD36
is co-regulated with T-cell growth factor IL-2 and has been linked
to glaucoma (32). It was postulated that the male predominance
of EoE may be related to the TSLP receptor residing within the
pseudoautosomal region 1 on the X and Y chromosomes (Xp22.3,
Yp11.3) (29). A more recent study showed that polymorphisms in
TSLP are risk factors for the development of EoE, independent of
allergy status and phenotypes (33). The same study found an asso-
ciation between polymorphisms in the thymic stromal lipoprotein
receptor (TSLPR) gene on Xp22.3/Yp11.3 and EoE in male par-
ticipants, suggesting a mechanism for the male predominance of
EoE. Moreover, primary esophageal epithelial cells were shown to
express TSLP mRNA in response to toll-like receptor 3 signaling,
suggesting a possible contribution of TSLP in the inflammation
and proliferation occurring in EoE affected esophagi. Further-
more, in a genome-wide microarray expression analysis, Lu et al.
(34) identified 32 miRNA specific for EoE. Of these, miRNA-21
and miRNA-223 were the most up-regulated in untreated EoE and
were down-regulated upon corticosteroid administration.
Despite this strong evidence supporting the genetic basis of EoE
pathogenesis, studies have shown that the familial pattern of inher-
itance of EoE shares an underlying pathogenesis with sporadic
cases of EoE (35).
THE PATHOPHYSIOLOGY OF EoE
Genetic predisposition may deem an individual vulnerable to the
environmental triggers resulting in EoE. Frequently, patients pre-
senting with EoE have a history of food (8) or aeroallergen (9)
hypersensitivity, elevated serum IgE, and responsiveness to diet
restriction (8, 10) or anti-allergy therapy (11, 36). Food hypersen-
sitivity has been reported in 19–73% of children and 13–25% of
adults with EoE (37). The reason for lower rates of food hypersen-
sitivity in adults is unclear, but this feature may mean that adults
are less responsive to diet restriction (8). Regardless, EoE is consid-
ered an immunoallergenic disorder, whereby esophageal inflam-
mation results from repeated exposure to food and aeroallergens
in genetically susceptible individuals (38).
The documented cytokine expression profile in the esophageal
tissue of EoE patients is that of a TH2 inflammatory response (13).
The activated TH2 response leads to the recruitment and activation
of eosinophils and mast cells, which degranulate, releasing prod-
ucts that instigate tissue damage and repair (39). Interestingly, TH1
cytokines including tumor necrosis factor (TNF)-α (expressed
by esophageal epithelial cells) (39) and interferon (IFN)-γ (up-
regulated by peripheral blood T cells) (40) are also found in
increased numbers in esophageal biopsies (41). This may explain
the non-IgE, type IV hypersensitivity (cell mediated) mechanism
of EoE (14). It is postulated that the EoE-defining endoscopic and
histologic manifestations are a culmination of the disease process
Frontiers in Pediatrics | Pediatric Gastroenterology and Hepatology May 2014 | Volume 2 | Article 41 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Raheem et al. Pathophysiology of EoE
(15) which, may have debilitating long-term effects including stric-
tures and food impactions in untreated or poorly managed cases
of EoE.
EOSINOPHILS
Eosinophils originate from CD34+myeloid precursor cells in the
bone marrow, mature to a granulated state and migrate to vascular
spaces (39). They tend to be present in all layers of the esophagus
in EoE, but predominate in the lamina propria and submucosal
regions. Eosinophils contain many preformed granule proteins
including eosinophil cationic protein (ECP), major basic protein
(MBP) eosinophil peroxidase (EPO), and eosinophil-derived neu-
rotoxin (EDN), which are released into tissues upon stimulation
and degranulation (42). Additionally, eosinophils synthesize and
release cytokines including IL-5, IL-13, transforming growth factor
(TGF)-α and -β, chemokines (eotaxins and RANTES), and lipid
mediators such as platelet activating factor (PAF) and leukotriene
C4 (42). The process of eosinophil maturation and migration is
stimulated by IL-5, IL-13, and granulocyte-macrophage colony
stimulating factor (GM-CSF) (9). Eosinophil-derived angiogenic
molecules may increase vascularity and facilitate inflammatory
cell recruitment. TGF-β1 and matrix metalloproteinase 9 (MMP)-
9 are fibrogenic mediators implicated in airway remodeling (42).
Additionally,MBP and MMP-9 have been implicated in the disrup-
tion of esophageal epithelial integrity though their involvement
in smooth muscles, fibroblasts, and cell-adhesion molecules (43).
These processes may culminate in overall esophageal dysfunction
through the consequent tissue remodeling.
Eosinophils are considered the main effector cells in fibrosis in
a variety of hypereosinophilic syndromes and eosinophil-related
allergic diseases including asthma and EoE (44). TGF-β (45) and
eosinophilic granule proteins MBP and EPO (46) are the key
eosinophil effector proteins. The importance of eosinophils in
mediating tissue fibrosis is supported by evidence in both murine
and human models (26). Interestingly, a recent study on fibrosis
reversal with dietary and steroid therapy showed that improve-
ment in esophageal eosinophilia and eosinophil degranulation
within the epithelium was strongly associated with fibrosis rever-
sal (47, 48) and symptom improvement. This finding is consistent
with Kagalwalla et al. (45), who found improvements in epithelial
remodeling in both dietary and corticosteroid therapy, and also
found these improvements to be directly associated with improve-
ment in esophageal eosinophilia (47). These findings not only
highlight the importance of targeting fibrosis reversal in treat-
ment of EoE, but also underline the importance of eosinophils in
tissue remodeling.
EOSINOPHIL-DERIVED ANGIOGENIC MOLECULES
Angiogenesis, a characteristic of chronic inflammation, may facil-
itate inflammatory cell recruitment (49). Increased numbers of
blood vessels are found in the lamina propria of pediatric patients
with EoE than those with reflux esophagitis (50). The same
study found an increased expression of the endothelial activation
marker, vascular cell-adhesion molecule (VCAM)-1, compared
with normal control subjects or patients with reflux esophagi-
tis. Moreover, VCAM-1 expression positively correlated (r = 0.61)
with esophageal eosinophil number, affirming its involvement in
EoE. Increased VCAM-1 expression causes increased tethering
of inflammatory cells to the endothelium of esophageal ves-
sels, thereby facilitating eosinophil infiltration into the esophagus
(51). Progressive tissue damage may result from this increased
inflammatory cell recruitment facilitated by angiogenic products.
EOSINOPHIL-DERIVED TGF-β1
Eosinophil-derived TGF-β1 has been implicated in the activation,
proliferation, and synthesis of extracellular matrices of epithe-
lial cells (39). Evidence suggests that TGF-β1 induces epithelial
basal zone hyperplasia, contributing to esophageal wall thickening
resulting in luminal narrowing (12). It also induces fibroblast acti-
vation and differentiation into myofibroblasts, with consequent
over-production of extracellular matrix (ECM), predisposing to
subepithelial fibrosis with consequent features of strictures and
food impactions (52). Finally, TGF-β1 may induce smooth muscle
hypertrophy, leading to thickening of the esophageal muscularis
propria (53).
Accordingly, TGF-β1 would be a good therapeutic target in
EoE. However, being a T-regulatory molecule, it is involved in the
regulation of normal immune systems and is vital in repair (39).
Consequently, the difficulty would lie in the localized delivery of a
drug targeting TGF-β1 to the esophagus alone, without interfering
with its normal functions in other tissues.
MBP AND MMP-9
Major basic protein levels correlate with basal cell hyperplasia
(46) and has been associated with loss of barrier function in
the esophageal epithelium (42). MBP has consequently been pro-
posed as a player in subepithelial fibrosis in EoE (54). It appears
to function by up-regulating the expression of fibroblast growth
factor (FGF)-9, a molecule involved in epithelial homeostasis and
proliferative response to injury (11). While initially being unchar-
acterized in the esophagus, FGF-9 has now been found in biopsy
specimens of patients with EoE (55), hence the interest in its up-
regulation by MBP. Another function of this molecule is smooth
muscle contraction through its action on muscarinic M2 recep-
tors, which may contribute to the dysphagia experienced by many
patients with EoE (56).
A molecule with similar function to MBP, MMP-9 can be gen-
erated by structural and inflammatory cells and has the ability
to secrete and activate latent matrix-bound growth factors (42).
MMP-9 can thus degrade proteoglycans thereby enhancing airway
fibrosis and smooth muscle proliferation (23). Although current
research implicate MBP and MMP-9 in cell proliferation and tissue
fibrosis, it must be highlighted that these molecules may have an
organ-specific function, in which case their effect on bronchial
remodeling may not be able to be generalized to esophageal
remodeling.
MAST CELLS
Mast cells, like eosinophils, are derived from CD34+ progenitors
in the bone marrow, with their differentiation being regulated
by surface c-kit receptor (CD117) (57). Mast cells contain sev-
eral preformed mediators including histamine, cytokines, serine
proteases (tryptase, chymase), and proteoglycans that are stored
in cytoplasmic granules (58). They have a central role in innate
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immunity especially in allergic diseases, being the predominat-
ing cells in IgE-mediated responses. Attwood and colleagues (3)
first discovered the presence of mast cells in the EoE inflamma-
tory infiltrate. Due to the suggested immunoallergenic nature of
EoE, the study of the involvement of mast cells in this disease has
recently increased (59).
The role of mast cells in EoE has been supported by both human
and animal studies. Several studies have identified increased mast-
cell numbers in patients with EoE (46, 60, 61). Further, epithelial
mast-cell infiltration was noted to precede eosinophil accumula-
tion in a guinea pig model of EoE (62). Mast-cell numbers were
also significantly increased after intranasal exposure to cockroach
and dust mite allergen in a murine model of EoE (63). Importantly,
studies on humans with EoE have found a correlation between
mast-cell counts and characteristic features of EoE including
intraepithelial eosinophil numbers, basal zone hyperplasia, and
eotaxin-3 level (30, 54).
The immunoregulatory function of mast cells has been increas-
ingly recognized in EoE (64). Through its action on H2 and
H4 receptors, mast-cell-derived histamine has been shown to
modulate immune responses by acting on dendritic cells and
T-lymphocytes (65). It may act to maintain a favorable environ-
ment for allergic immune responses by recruiting T-lymphocytes,
enhancing the proliferation of eosinophils in the bone marrow and
inducing B-cell class switching to IgE production (66). Addition-
ally, mast-cell-derived proteoglycans such as heparin are known
to potentiate eotaxin-induced eosinophil recruitment in vivo (67),
highlighting a key combinatory role amongst eosinophils and mast
cells in EoE pathogenesis.
Mast cells may also have an effector function through specific
enzymes. Mast-cell-specific genes encoding for proteins includ-
ing chymase, tryptase, and carboxypeptidase A3 are significantly
unregulated in EoE (30). These proteins are known to increase
mucus secretion and smooth muscle contraction in the bronchi
of asthmatics (39). Furthermore, Chehade and colleagues (54)
found increased expression of tryptase-positive mast cells that
produced TGF-β contributing to tissue remodeling. Addition-
ally, mast cells have been found in the muscle layers of the
esophagus and may cause contraction of muscularis mucosae
through histamine-activated acetylcholine resulting in tracheal-
ization of the esophagus, as observed endoscopically in patients
with EoE (68).
Despite evidence supporting mast-cell involvement in EoE,
there is currently no evidence supporting therapies targeting mast
cells in EoE. Lucendo et al. (59) found no statistical decrease in
mast-cell numbers in EoE patients following 3 months of gluco-
corticoid therapy (fluticasone propionate 500µg b.i.d). In the
same study however, there was a significant reduction in IgE
positive cells. A randomized controlled trial found a significant
decrease in mast-cell numbers in pediatric patients with EoE
after 3 months fluticasone treatment with fluticasone (880µg
b.i.d) (69). However, 1-month treatment of EoE in a pediatric
cohort, with the mast-cell stabilizer sodium cromoglycate (100 mg
q.i.d), did not significantly affect symptoms or eosinophil counts
(2). Overall, this suggests that although the involvement of mast
cells is clear, its role in the pathogenesis of EoE is not yet fully
characterized.
THE ROLE OF TH2 TYPE INFLAMMATION IN EoE PATHOPHYSIOLOGY
Serum IgE measurements demonstrate that the majority (80%) of
patients with EoE have identifiable hypersensitivity to both food
and aeroallergens (70). Inferentially, the majority of EoE cases
may be associated with an IgE-mediated type 1 hypersensitivity
reaction. Such reactions involve antigen presentation to CD4+
T-helper 2 (TH2) cells, which stimulate B-cell class switching to
IgE production (39). This differs from TH1 responses where the
immune system is directed toward a chronic intracellular infec-
tion, involving the activation of cytotoxic T cells and macrophages
by TH1 cytokines such as IFN-γ. Most adaptive immune responses
are a mixture of both TH1 and TH2 however, as suggested by the
cytokine expression profile, EoE is a predominantly TH2-mediated
condition (13). The following section discusses the contribu-
tions of B cells and TH2 cytokines such as IL-5 and IL-13 in the
pathogenesis of EoE.
B CELLS
In allergic contexts, TH2 cells stimulate B-cell (CD20+) class
switching to produce IgE antibodies. IgE binds to its respective
high-affinity receptor (FCεRI) present on the surface of mast cells,
and this complex can then bind to an antigen, leading to mast-
cell activation and degranulation (57). Unfortunately, despite this
knowledge of B cells in allergic reactions, their role in EoE is
poorly understood. One study found B cells to be significantly
increased in the epithelium and lamina propria of EoE patients
compared to healthy controls, and this value correlated signif-
icantly (r = 0.744) with mast-cell number (71), which in turn
has been shown to correlate with eosinophil numbers (54). In
Vicario and colleagues (71) study, evidence showed local B lym-
phocyte class switching to IgE expression (71). Another study
found no change in B-cell numbers in untreated or corticosteroid-
treated EoE patients (72). The possible discrepancy between the
studies may be due to differences in patient demographics, and
further such studies are required to substantiate the role of B cells
in EoE.
CYTOKINES
Interleukin-4 is responsible for the differentiation of naïve
T-helper (TH0) cells into activated TH2 cells. IL-4 stimulates
B-cell proliferation and maturation within plasma cells, regulates
class switching of antibodies, and increases IgE production. Blan-
chard and colleagues (13) found no significant differences in the
level of IL-4 between EoE patients and non-EoE controls, however
IL-4 mRNA levels were significantly decreased in EoE patients
following glucocorticoid therapy or elemental diets. In the same
study, elevated IL-4 and IL-5 mRNA levels were found in allergic
EoE patients compared to their non-allergic counterparts. Inter-
estingly, there was no statistical difference in eotaxin-3 or IL-13
mRNA levels between the two patient groups. This may indicate
a dysregulation of IL-4 and IL-5 in allergic EoE patients which
possibly reflect their systemic allergic history rather than activity
of the disease (13). However, this difference in cytokine expres-
sion between allergic and non-allergic EoE patients may open
avenues for further research such as investigating possible dif-
ference in severity and response to treatments between the two
patient groups.
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Interleukin-5 functions in the proliferation, differentiation, and
survival of eosinophils, TH0 cells, and mast cells (39). Mishra
et al. (9) demonstrated a murine model for aeroallergen-induced
esophageal eosinophilia by challenging mice withAspergillus fumi-
gatus. In this model, IL-5 was shown to be essential in aeroallergen-
induced eosinophil recruitment to the esophagus (73). More
recently, Blanchard et al. (13) found a significant increase in
IL-5 mRNA in EoE patients compared to inactive EoE and healthy
controls. The same study confirmed the importance of eotaxin-
3 in the IL-5-dependent induction of esophageal eosinophilia as
a 15-fold decrease in eosinophil number was found in eotaxin-
deficient mice when subjected to the same aeroallergen challenge
(73). IL-5 appears to function by enhancing eosinophil respon-
siveness to endogenous chemokines expressed by the esophagus
such as eotaxin-3 (discussed later) (73).
Despite compelling evidence suggesting the importance of
IL-5 in EoE, drugs targeting IL-5 have shown little clinical effi-
cacy. A randomized controlled trial evaluating the anti-IL-5 anti-
body mepolizumab showed little clinical improvement, despite
the decreased tissue eosinophilia compared to placebo controls
(12). This questions current understanding of the mechanism
by which IL-5 contributes to EoE, or that perhaps esophageal
damage may prevail through other mechanisms, aside from that
of IL-5-recruited eosinophils. Concordantly, reslizumab, another
anti-IL-5 antibody reduced eosinophil counts in esophagi of chil-
dren and adolescents, but symptom improvements were observed
in all treatment groups and were not associated with changes in
eosinophil number in the esophagus (74).
Interleukin-13, similar in structure and function to IL-4, may
have a role in propagating the inflammatory response toward a
TH2 mechanism, and has also been implicated in tissue fibrosis
(39). Interestingly, IL-13-induced lung eosinophilia consequently
induced esophageal eosinophilia as well (75), suggesting a possible
intimate connection between respiratory and esophageal epithelia,
or simply the systemic allergic reaction in both cases. Studies on
bronchial remodeling in asthma, have shown that IL-13 is essen-
tial for tissue fibrosis and airway mucous production (52). Similar
findings were seen in EoE, when Blanchard and colleagues (60)
found a 16-fold increase in IL-13 mRNA in biopsies of pediatric
patients with esophageal fibrosis, compared to non-EoE controls.
IL-13 is also known to stimulate eotaxin-3 production by epithelial
cells, which in turn stimulates eosinophil recruitment (60).
Additionally, IL-13 may stimulate fibroblasts to overexpress
periostin and down-regulate filaggrin. Periostin is an ECM mol-
ecule that promotes eotaxin-induced eosinophil recruitment and
regulates eosinophil adhesion (76). Filaggrin is a structural barrier
protein in skin keratinocytes; down-regulation of this protein has
been implicated in the impairment of esophageal barrier function
and development of atopic dermatitis (76). Filaggrin is a mem-
ber of the epithelial differentiation cluster (EDC), and together
with involucrin (another EDC member), prevents the proteolytic
destruction of keratin during differentiation of epidermal cells
(77, 78). This forms an important barrier function in cornified
epithelial cells, although its function in esophageal epithelial cells
is less clear. A recent study on the effect of IL-13 on genes involved
in epithelial differentiation concluded that IL-13 plays a large role
in the up-regulation of genes such as Ki67 and down-regulation
of EDC genes such as filaggrin and involucrin, which cumulatively
contribute to the eotaxin-mediated recruitment of eosinophils to
the esophageal epithelium. Not only does this open an avenue
for further research on possible therapeutic strategies targeting
IL-13 in EoE, but also suggests the importance of IL-13 in the
pathogenesis of EoE.
Recently, Zhu et al. (79) found that IL-15 is involved in the
induction of eosinophil-selective cytokines and chemokines by
CD4+ T cells. This study found a 6- to 10-fold increase in the
levels of both IL-15 and its receptor IL-15Rα in esophageal tissues,
and a twofold increase in serum IL-15 protein levels in patients
with EoE. Additionally, the level of esophageal eosinophilia in
patients both treated and untreated EoE correlated significantly
with the IL-15 transcript. Importantly, the IL-15Rα-deficient mice
were protected from the development of experimental EoE (79).
Interestingly however, these mice were not protected from airway
inflammation, suggesting that IL-15 many have an organ-specific
mechanistic induction of esophageal eosinophilia in mice.
EOTAXINS
The three eotaxins are chemokines with selective eosinophil-
chemoattractant activity and act on CCR-3 receptors (39).
Blanchard and colleagues (30) found an increase in eotaxin-
3 levels in esophageal biopsies of patients with EoE. In the
same study, these levels correlated with esophageal eosinophil
numbers. Konikoff and colleagues (80) found a correlation
(r = 0.32) between eotaxin-3 protein level in peripheral blood
and esophageal eosinophilia. Interestingly, eotaxin-1 and eotaxin-
2 levels did not correlate. Battacharya and colleagues (81) however
showed contradicting findings with increased eotaxin-1, -2, and -3
levels in EoE, but also no correlation between eotaxin-3 levels and
tissue eosinophilia.
A recent genome-wide expression analysis identified eotaxin-3
as the single most up-regulated gene in EoE (30). Furthermore,
a single nucleotide polymorphism in the untranslated region of
the eotaxin-3 gene is associated with EoE (30). Interestingly, this
expression profile is not associated with GERD, a disease triggered
by acid reflux, also associated with esophageal eosinophilia (57).
Blanchard et al. (30) found a strong correlation between eotaxin-3
level and disease severity, determined by the degree of basal cell
hyperplasia and numbers of eosinophils and mast cells. In the
same study, EoE could not be induced in CCR-3-deficient mice
(30). Additionally, IL-5 and IL-13 have shown to increase eotaxin-3
release by esophageal epithelial cells (81) suggesting the combined
contributions of these molecules in esophageal eosinophilia.
Eotaxin-3 has been increasingly recognized as a more accu-
rate biomarker for the diagnosis of EoE. Some patients with
GERD also present with eosinophil numbers >15/hpf, thus rais-
ing questions regarding the accuracy of using peak intraepithelial
eosinophil counts as a diagnostic feature of EoE (6). The same
study concluded that increased numbers of cells staining for MBP
and eotaxin-3 was more predictive of EoE than eosinophil counts
alone. This suggests possible flaws in current diagnostic criteria,
and highlights the importance of eotaxin-3 in EoE.
Combining this evidence, the importance of eotaxin-3 in
esophageal eosinophilia is widely accepted. It is proposed that
IL-13, produced by TH2 inflammatory cells under allergic contexts
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stimulates the production of eotaxin-3 by epithelial cells. IL-5 and
eotaxin-3 may act synergistically to induce esophageal eosinophil
infiltration, allowing eosinophilic inflammation to ensue. How-
ever, the reason for which this inflammatory process is restricted
to the esophagus remains elusive. Regardless, this localized func-
tion of eotaxin-3 in EoE may be important in minimizing
side-effects, if it were to be considered a future therapeutic
target.
ESOPHAGEAL EPITHELIUM
The esophagus is composed of stratified squamous epithelium,
protected by a variety of organ-specific molecules such as mucous
and antibodies. Additionally, the epithelium is a potent reser-
voir of cytokines and lipid mediators, which normally func-
tions to cleanse the epithelial surface (42). Disease develops
when these functions are dysregulated and disrupted (49). In an
allergen-induced TH2 response, molecules such as IL-13 stimu-
late esophageal epithelial cells to produce eotaxin-3 (30) which
in turn leads to esophageal eosinophil recruitment. The resulting
activation and degranulation releases mediators that cause tissue
remodeling.
Epithelial to mesenchymal transformation (EMT) is a process
whereby epithelia lose many characteristics including polarity, and
acquire properties of mesenchymal cells, including motility and
loose cell-adhesion (45). It facilitates the development of tissue
fibrosis in many organs in response to injury, including the lungs
(45). TGF-β and MBP released by eosinophils or damaged epithe-
lium, may induce EMT and contribute to subepithelial fibrosis
(82). The degree of EMT in patients with EoE has been shown
to correlate with the amount of TGF-β1, eosinophil number, and
amount of subepithelial fibrosis (82). Eosinophils can also directly
induce the expression of factors relevant to EMT and fibrosis in
epithelial cells, such as TGF-α, MMP-9, and others, through the
secretion of MBP and cytokines such as IL-13 (45).
Blanchard and colleagues (30) suggested that intestinal
epithelia are capable of releasing eotaxins, which are essen-
tial in eosinophil migration to the GIT. Epithelia also promote
eosinophil survival, by releasing epithelial-derived GMSF, which
delays apoptosis (42). Additionally, Hahn and colleagues (83)
found that during allergic inflammation, there is an increased
expression of nerve growth factor in airway epithelial cells,
which may promote the survival of tissue eosinophils. How-
ever esophageal epithelial cells may have an organ-specific
interaction with eosinophils, as supported in studies show-
ing the necessity of eotaxin-3 in the induction of esophageal
eosinophilia (30, 73).
Esophageal epithelial cells also express IL-4α, IL-13Rα1, and
IL-13Rα2, which are all the components of the IL-13 receptor, ren-
dering esophageal epithelial cells vulnerable to influence by IL-13.
As mentioned previously, IL-13 plays a large role in the eotaxin-
mediated recruitment of eosinophils to the esophageal mucosa,
through the stimulation of epithelial cells to up-regulate some
genes and down-regulate others. Interestingly, the same study
found that biopsies of normal and EoE diseased esophagi, both
showed an over-expression of eotaxin-3 in response to IL-13, sug-
gesting that IL-13/IL-13 receptor/STAT6 pathway is similar in both
normal and EoE patients (67).
Table 1 | Key findings and current treatments.
KEY FINDINGS
EoE is an inflammatory disorder that is most likely initiated by a
hypersensitivity reaction to aero- or food allergens, with a late-phase
characterized by eosinophil recruitment and subsequent tissue damage
EoE predominates in the Caucasian male population. Mutations in the
TSLP gene may provide a mechanism for the male predilection of EoE
Eosinophil-derived molecules including TGF-β1, MBP, and MMP-9 play a
central role in fibrosis
Some mast-cell-derived molecules such as heparin potentiate
eotaxin-mediated eosinophil recruitment to the esophagus, while others
such as histamine may contribute to the abnormal functioning of
esophageal musculature through its effect on enteric nerves
IL-5 was shown to be essential in aeroallergen-induced eosinophil
recruitment to the esophagus, and IL-15 many also contribute to the same
process
IL-13 plays a large role in the up-regulation of genes such as Ki67 and
down-regulation of EDCs such as filaggrin and involucrin, which
cumulatively contribute to the eotaxin-mediated recruitment of eosinophils
to the esophageal epithelium
MBP and eotaxin-3 levels in esophageal biopsies may be more accurate
diagnostic biomarkers of EoE
Esophageal epithelial cells are a potent reservoir for cytokines and express
receptors such as IL-4α, IL-13Rα1, and IL-13Rα2, making them vulnerable to
molecules such as IL-13
CURRENT EFFECTIVETREATMENTS FOR EoE
Topical corticosteroids
Fluticasone propionate
Budesonide
Elimination diets
Elemental diets
Esophageal dilation to treat strictures
CONCLUSION
In summary, EoE is an inflammatory disorder (Table 1) that
may be initiated by a hypersensitivity reaction to aero- or
food allergens, with a late-phase characterized by eosinophil
recruitment and subsequent tissue damage. It is currently
characterized by excessive intraepithelial eosinophils, however
emerging research shows that increased levels of eosinophil-
degranulation products (MBP) and eotaxin-3 may be more accu-
rate biomarkers of EoE. EoE has incompletely defined patho-
physiology, having characteristics of mainly TH2 type immune
responses but also includes some TH1 cytokines which appear
to strongly contribute to tissue fibrosis with esophageal epithelial
cells providing a hospitable environment for this inflammatory
process.
Eosinophil-degranulation products appear to play a central
role in tissue remodeling in EoE. Of note, TGF-β1, MBP, and
MMP-9 affect the esophageal epithelium by inducing EMT, inter-
fering with function of esophageal musculature and cellular
integrity. This remodeling and dysregulation predisposes to
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fibrosis. Mast-cell-derived molecules such as histamine may affect
enteric nerves and may act in concert with TGF-β to disrupt
the normal functioning of esophageal musculature. Addition-
ally, the esophageal epithelium may facilitate the inflammatory
process under pathogenic contexts such as in EoE. Collectively,
these contribute to the characteristic histological features of EoE
such as subepithelial fibrosis and esophageal thickening, leading
to endoscopic findings of luminal narrowing, stricture forma-
tion, and trachealization, resulting in symptomatic presentations
such as food impactions, dysmotility, and dysphagia. The over-
all inflammatory response is regulated and propagated with the
assistance of eosinophil-derived angiogenic products facilitat-
ing recruitment of inflammatory mediators, and also the reg-
ulatory functions of molecules such as IL-13 and also mast
cells.
The understanding of EoE is still in its infancy. While allergy
is implicated, other mechanisms of EoE are also acknowledged in
the literature, which implicate mainly eosinophil degranulation
and eosinophil-mast-cell cross talk, in disease pathogenesis. While
future research may identify possible therapeutic targets, localiz-
ing the delivery of these therapies to the esophagus alone remains
a challenge. Furthermore, as discussed, emerging evidence sug-
gests a genetic contribution to EoE. This is significant, as recent
studies have demonstrated the coexistence of EoE with another
genetically inherited condition, CD (27, 28). Further research is
required to ascertain the effect of CD on the presentations and
treatment outcomes of EoE.
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